A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors

被引：0
|
作者：
Sausville, E. [1 ,2 ,3 ,4 ,5 ]
Garbo, L. [1 ,2 ,3 ,4 ,5 ]
Weiss, G. J. [1 ,2 ,3 ,4 ,5 ]
Anthony, S. [1 ,2 ,3 ,4 ,5 ]
Shkolny, D. [1 ,2 ,3 ,4 ,5 ]
Yurkovetskiy, A. V. [1 ,2 ,3 ,4 ,5 ]
Bethune, C. [1 ,2 ,3 ,4 ,5 ]
Fram, R. J. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] New York Oncol Hematol, Albany, NY USA
[3] TGen, Clin Res Serv, Scottsdale, AZ USA
[4] Mersana Therapeut Inc, Cambridge, MA USA
[5] Covance Bioanalyt, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2574
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors
    Zhu, Andrew X.
    Ready, Neal
    Clark, Jeffrey W.
    Safran, Howard
    Amato, Antonino
    Salem, Nadia
    Pace, Silvia
    He, Xiaoying
    Zvereva, Nela
    Lynch, Thomas J.
    Ryan, David P.
    Supko, Andjeffrey G.
    CLINICAL CANCER RESEARCH, 2009, 15 (01) : 374 - 381
  • [32] Phase I study to determine the safety and pharmacokinetics of 4-hour intravenous infusion of TAS-106 on a once per week for 3 consecutive weeks every 28-day schedule in patients with solid tumors
    Chadha, R.
    Mita, A.
    Iwasaki, M.
    Lassere, Y. M.
    Bogaard, K. R.
    Waldrum, S. A.
    Abbruzzese, J. L.
    Thomas, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors
    Massard, Christophe
    Majem, M.
    Soria, Jean-Charles
    Salazar, R.
    Deutsch, Eric
    Garcia, M.
    Oaknin, A.
    Soto, A.
    de las Heras, B.
    Armand, Jean-Pierre
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3335S - 3336S
  • [34] Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors
    Salazar, R
    Soria, JC
    Majem, M
    Ropert, S
    Garcia, M
    Armand, JP
    Lázaro, LL
    Escolar, L
    de las Heras, B
    ANNALS OF ONCOLOGY, 2006, 17 : 50 - 50
  • [35] Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
    Wakelee, H. A.
    Patnaik, A.
    Sikic, B. I.
    Mita, M.
    Fox, N. L.
    Miceli, R.
    Ullrich, S. J.
    Fisher, G. A.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 376 - 381
  • [36] A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
    Desai, AA
    Schilsky, RL
    Young, A
    Janisch, L
    Stadler, WM
    Vogelzang, NJ
    Cadden, S
    Wright, JA
    Ratain, MJ
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 958 - 965
  • [37] Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors.
    Armand, JP
    Majem, M
    Soria, JC
    Garcia, M
    Ropert, S
    Salazar, R
    Lazaro, LL
    Escolar, L
    de las Heras, B
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [38] A phase I pharmacokinetic study of PM00104 (ZalypsisA®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
    Capdevila, J.
    Clive, S.
    Casado, E.
    Michie, C.
    Piera, A.
    Sicart, E.
    Carreras, M. J.
    Coronado, C.
    Kahatt, C.
    Soto Matos-Pita, A.
    Fernandez Teruel, C.
    Siguero, M.
    Cullell-Young, M.
    Tabernero, J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1247 - 1254
  • [39] A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
    J. Capdevila
    S. Clive
    E. Casado
    C. Michie
    A. Piera
    E. Sicart
    M. J. Carreras
    C. Coronado
    C. Kahatt
    A. Soto Matos-Pita
    C. Fernandez Teruel
    M. Siguero
    M. Cullell-Young
    J. Tabernero
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1247 - 1254
  • [40] A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
    Gelmon, K
    Hirte, H
    Fisher, B
    Walsh, W
    Ptaszynski, M
    Hamilton, M
    Onetto, N
    Eisenhauer, E
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 263 - 275
12345